MedTrace Logo

Docetaxel in Non Small Cell Lung Cancer (NSCLC)

NCT00263016 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2008-03-20

No results posted yet for this study

Summary

Primary Objective:

* To compare the tumour response rate of combination chemotherapy irinotecan/cisplatin (IC) versus docetaxel/cisplatin (DC) in advanced NSCLC patients who responded to 3 courses of docetaxel/cisplatin.

Secondary Objectives :

* To compare the time to progression after chemotherapy treatment between the IC and DC arms of treatment.
* To compare the toxicity profile of the IC and DC arms of treatment.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Docetaxel

Sponsors & Collaborators

Principal Investigators

  • Iris CHAN, MD · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00263016 on ClinicalTrials.gov